Evaluating only Arterys’s profile at its peak — without knowing the outcome — the model ranked Acquisition gone wrong as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
PRODUCT LAUNCH
ACQUISITION ATTEMPT
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Arterys built cloud-based AI tools for medical imaging analysis — specifically cardiac and oncology MRI and CT scan interpretation. It secured multiple FDA clearances, a major achievement in medical AI. Tempus AI (genomics and data) acquired Arterys in 2022 to expand its clinical AI capabilities. The Arterys product was wound down as a standalone platform and the team was absorbed.
Lesson
“Medical AI clearances create regulatory moats but not commercial moats — large health data companies will always be able to absorb FDA-cleared tech.”
Failure anatomy
Collapse type
Acqui-hire
📉 MEDIUM
Hype cycle
Digital Health
Moat type
IP
Fatal mistake
Acquisition Failure
// engine intelligence on Arterys
Tier 1 · instant unlock🔒 free account
Loading engine analysis…
Tier 2 · the productAnalyst · €149/mo
What you see retrospectively on Arterys, applied predictively to your companies:
→Cross-reference this pattern against your live portfolio
→Alerts when a company you track starts matching this profile